• 1
    Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499504.
  • 2
    Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. Risk within the ‘normal’ weight range. JAMA 1995; 273: 4615.DOI: 10.1001/jama.273.6.461
  • 3
    Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 93742.
  • 4
    Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R. Insulin sensitivity and atherosclerosis. The insulin resistance atherosclerosis study (IRAS) investigators. Circulation 1996; 93: 180917.
  • 5
    Serrano Rios M. Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998; 28 (Suppl. 2): 148.DOI: 10.1046/j.1365-2362.1998.0280s2014.x
  • 6
    Colwell JA. Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism 1997; 46 (Suppl. 1): 14.
  • 7
    Brand FN, Kannel WB, Evans J, Larson MG, Wolf PA. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study. Am Heart J 1998; 136: 91927.
  • 8
    Jung RT. Obesity as a disease. Br Med Bull 1997; 53: 30721.
  • 9
    Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97: 260110.
  • 10
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 11526.DOI: 10.1056/NEJM199901143400207
  • 11
    Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105: 32S39S.DOI: 10.1016/S0002-9343(98)00209-5
  • 12
    Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 1629.
  • 13
    Palareti G, Legnani C, Poggi M, Parenti M, Babini AC, Biagi R, Baraldi L, Luchi A, Capelli M, Coccheri S. Prolonged very low calorie diet in obese subjects reduces factor VII and PAI but not fibrinogen levels. Fibrinolysis 1994; 8: 1621.DOI: 10.1016/0268-9499(94)90027-2
  • 14
    Mehrabian M, Peter JB, Bernard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84: 2532.
  • 15
    Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: effect of dieting with or without exercise in overweight postmenopausal women. Arterioscler Thromb Vasc Biol 1996; 16: 3815.
  • 16
    Sundell IB, Dahlgren S, Rånby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989; 3: 513.DOI: 10.1016/0268-9499(89)90028-3
  • 17
    Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 30: 128794.DOI: 10.1056/NEJM199405053301808
  • 18
    Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 8995.DOI: 10.1016/S0140-6736(00)03539-X
  • 19
    ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268: 1292300.DOI: 10.1001/jama.268.10.1292
  • 20
    Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27: 90711.DOI: 10.1038/sj.ijo.0802312
  • 21
    TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 157783.
  • 22
    CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 132939.DOI: 10.1016/S0140-6736(96)09457-3
  • 23
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 47984.DOI: 10.1001/jama.278.6.479
  • 24
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999; 99: 19518.
  • 25
    Fitzgerald GA. Dipyridamole. N Engl J Med 1987; 316: 124757.
  • 26
    Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 2925.
  • 27
    Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 4269.
  • 28
    Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Co-activation of platelets by prolactin or leptin—pathophysiological findings and clinical implications. Horm Metab Res 2004; 36: 16.DOI: 10.1055/s-2004-814200
  • 29
    Wallaschofski H, Kobsar A, Sokolova O, Siegemund A, Stepan H, Faber R, Eigenthaler M, Lohmann T. Differences in platelet activation by prolactin and leptin. Horm Metab Res 2004; 36: 4537.DOI: 10.1055/s-2004-825727